ArticleInternational journal of cardiology. Heart & vasculature2022
Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA
Article in International journal of cardiology. Heart & vasculature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Addition of malignancy into the CHADS2/CHA2DS2VASc score: better prediction of stroke risk in individuals with cancer and atrial fibrillation.Cardio-oncology (London, England) · 2026Article
- Catheter-Based Valvular and Structural Interventions in Cancer Patients.Current cardiology reports · 2026Review
- Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions.Journal of thrombosis and thrombolysis · 2025Review
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- The B-SCancers · 2025Article
- Review
- The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation: A Population-Based Cohort Study.JACC. CardioOncology · 2025Article
- Vascular Complications of Atrial Fibrillation in Patients With Cancer.JACC. CardioOncology · 2025Article
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2024Article
- Performance of CHAEuropean heart journal open · 2024Article
- Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.Journal of thrombosis and thrombolysis · 2024Article
- Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024Article
- The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation.Leukemia & lymphoma · 2024Article
- Recent highlights on specific aspects of oral anticoagulation in difficult clinical scenarios from theInternational journal of cardiology. Heart & vasculature · 2023Article
- Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population.Current treatment options in oncology · 2023Review
- Revisiting important issues in cancer and atrial fibrillation.Research and practice in thrombosis and haemostasis · 2023Article
- Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients.JACC. CardioOncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Introduction: Atrial fibrillation (AF) is associated with an increased risk of stroke. Despite evidence linking cancer and thrombosis, cancer is not part of the CHA Hypothesis: Cancer is an independent risk factor for thromboembolic stroke in patients with AF. Method: The SEER database was utilized to identify patients with lung, colon, breast, and prostate cancers with AF and no prior diagnosis of stroke and. compared to controls within the dataset. The primary endpoint was rates of stroke per 100 person-years. Cox regression modeling and a nested model comparing CHA Results: A total of 101,185 patients were included in the analysis, with 48,242 in the Cancer and 52,943 in the Non-cancer Group. Stroke rate per 100 person-years was significantly higher in the Cancer Group. The CHA Conclusion: Cancers increase the risk of stroke in patients with AF. Consideration should be given to the addition of cancer to the clinical scoring system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.